BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Advance Gene Engineering\, Persistence\, and Scalable Expansio
 n of NK\, Gamma-Delta T\, and NKT Cell Therapies to Develop Cost-Effectiv
 e Allogeneic Treatments for Liquid and Solid Tumors\n\n2020 has been a ga
 me-changing year for the NK cell community. Positive clinical results hav
 e forced the field to wake up to the potential of these pioneering approa
 ches. However\, this increased clinical understanding highlights the chal
 lenges in producing long-lasting\, scalable products.\n\nSupporting the f
 ield since its' infancy\, the Innate Killer Summit is returning for the 6
 th year as the leading\, industry-defining forum dedicated to advancing t
 he field to achieve clinical success.\n\nSpanning the current drug develo
 pment landscape\, from improving CAR transduction in discovery through to
  cryopreservation in clinical manufacture\, join the first and only compr
 ehensive meeting to exclusively focus on the clinical and commercial deve
 lopment of innate cell therapies.\n\nJoin over 200 experts from Nkarta Th
 erapeutics\, Kiadis Pharma\, the FDA\, Celularity\, Century Therapeutics 
 and more\, to comprehensively analyze cell sources\, combination approach
 es\, regulatory processes\, as well as the evolving understanding of NK t
 herapies for viral infection including COVID-19.\n\nPromising novel unpub
 lished data\, interactive discussion\, and engaging networking opportunit
 ies leave the Innate Killer Summit equipped with new collaborations and l
 essons learned to capitalize on the easier applicability\, regulatory and
  compliance of innate therapies compared to T cell approaches.\n\nhttps:/
 /innate-killer.com/\n\n23-25 March\, 20219.30am-6pm EST | 6.30am-3pm PST\
 n\nContact:info@hansonwade.com\n
DTEND:20210325T180000
DTSTAMP:20260512T220031Z
DTSTART:20210323T090000
LOCATION:Online\, \,
SEQUENCE:0
SUMMARY:Advance Gene Engineering\, Persistence\, and Scalable Expansion of
  NK\, Gamma-Delta T\, and NKT Cell Therapies to Develop Cost-Effective Al
 logeneic Tre...
UID:ca3942ed-be43-483f-a73d-7785e8228c18
END:VEVENT
END:VCALENDAR